Syphilis, caused by Treponema pallidum, has resurged globally in recent years, particularly in East Asia, highlighting the urgent need for preventive vaccines. Despite being a well-characterized pathogen, traditional vaccine development for T. pallidum faces substantial challenges due to its inability to be cultured in artificial media. This study presents the development of a novel oral vaccine candidate utilizing recombinant T. pallidum outer membrane proteins TprK and Tp0751 expressed in yeast (Saccharomyces Boulardii). Our approach incorporates a gene cassette containing the conserved N-terminal region of TprK, cholera toxin B subunit (CtB) as an immune adjuvant, and Tp0751, connected by glycine-serine flexible linkers under the control of the ADH promoter. This strategy aims to overcome the cultivation limitations of T. pallidum while potentially inducing protective mucosal immunity through oral administration. Structural analysis using AlphaFold predictions confirms the stability of the recombinant construct. This research represents a significant advancement toward developing an accessible and effective vaccine against syphilis, with important implications for global public health.